Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil und leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy.
Authors
Siveke, JCubillo, A
Blanc, J
Melisi, D
Von Hoff, D
Wang-Gillam, A
Chen, L
Becker, C
Mamlouk, K
Belanger, B
Yang, Y
de Long, F
Hubner, Richard A
Affiliation
University Hospital Essen, West German Cancer Center, Essen, GermanyIssue Date
2017